QI
VNDA icon

QS Investors’s Vanda Pharmaceuticals VNDA Stock Holding History

QS Investors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$614K Sell
28,500
-269
-0.9% -$4.81K 0.01% 658
2021
Q1 		$433K Sell
28,769
-600
-2% -$9.71K 0.01% 848
2020
Q4 		$386K Buy
29,369
+600
+2% +$7.22K ﹤0.01% 899
2020
Q3 		$278K Sell
28,769
-119,900
-81% -$1.28M ﹤0.01% 953
2020
Q2 		$1.7M Sell
148,669
-300
-0.2% -$3.4K 0.02% 552
2020
Q1 		$1.54M Buy
148,969
+200
+0.1% +$2.48K 0.02% 512
2019
Q4 		$2.41M Sell
148,769
-2,100
-1% -$31.8K 0.02% 530
2019
Q3 		$2M Buy
150,869
+200
+0.1% +$2.79K 0.02% 568
2019
Q2 		$2.12M Sell
150,669
-2,289
-1% -$36.4K 0.02% 569
2019
Q1 		$2.81M Sell
152,958
-41,811
-21% -$953K 0.03% 466
2018
Q4 		$5.09M Sell
194,769
-107,861
-36% -$2.54M 0.07% 211
2018
Q3 		$6.95M Hold
302,630
– – 0.07% 188
2018
Q2 		$5.76M Buy
302,630
+20
+0% +$334 0.06% 244
2018
Q1 		$5.1M Sell
302,610
-22,975
-7% -$385K 0.05% 257
2017
Q4 		$4.95M Sell
325,585
-9,841
-3% -$146K 0.05% 303
2017
Q3 		$6M Sell
335,426
-10,933
-3% -$183K 0.05% 248
2017
Q2 		$5.65M Sell
346,359
-3,262
-0.9% -$47K 0.05% 267
2017
Q1 		$4.89M Sell
349,621
-1,620
-0.5% -$23.1K 0.04% 301
2016
Q4 		$5.6M Sell
351,241
-119,724
-25% -$1.92M 0.05% 307
2016
Q3 		$7.84M Hold
470,965
– – 0.06% 249
2016
Q2 		$5.27M Buy
470,965
+23,232
+5% +$225K 0.04% 372
2016
Q1 		$3.74M Buy
447,733
+1,087
+0.2% +$8.92K 0.04% 485
2015
Q4 		$4.16M Buy
446,646
+267,765
+150% +$2.67M 0.04% 456
2015
Q3 		$2.02M Buy
178,881
+68,395
+62% +$837K 0.02% 619
2015
Q2 		$1.4M Hold
110,486
– – 0.02% 691
2015
Q1 		$1.03M Hold
110,486
– – 0.01% 744
2014
Q4 		$1.58M Buy
+110,486
New +$1.31M 0.02% 636

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

QS Investors's VNDA Position: Q2 2021 in Review

QS Investors reduced its Vanda Pharmaceuticals (VNDA) stake by 0.94% in Q2 2021, selling an estimated $4.81K and leaving 28,500 shares worth $614K. The position accounts for 0.01% of the portfolio, ranked #658.

QS Investors first reported a position in VNDA in Q4 2014 and has held it in 27 quarters since. The position peaked at $7.84M in Q3 2016. 181 funds tracked by Wall St. Rank hold VNDA as of Q2 2021.

  • QS Investors held 28,500 shares of Vanda Pharmaceuticals worth $614K as of Q2 2021.
  • QS Investors sold 269 Vanda Pharmaceuticals shares in Q2 2021, an estimated $4.81K.
  • Vanda Pharmaceuticals made up 0.01% of QS Investors's portfolio in Q2 2021, its #658 holding.
  • QS Investors first reported a position in Vanda Pharmaceuticals in Q4 2014 and has held it in 27 quarters since.
  • QS Investors's Vanda Pharmaceuticals position peaked at $7.84M in Q3 2016.
  • 181 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.